The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis

SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) has shown variable response rates between 9% and 39%. Therefore, better criteria are needed that help doctors to identify patients who will show a favorable outcome to PRRT, and which patients may not. The so...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Ruhwedel, Tristan, Rogasch, Julian M. M., Huang, Kai, Jann, Henning, Schatka, Imke, Furth, Christian, Amthauer, Holger, Wetz, Christoph
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7915791/
https://ncbi.nlm.nih.gov/pubmed/33562643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040635
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller